ArriVent to Present Firmonertinib Phase 3 Supporting Data and ARR-002 ADC Efficacy
ArriVent will present crystal-structure and xenograft findings for its brain-penetrant EGFR inhibitor firmonertinib at AACR, bolstering its pivotal Phase 3 trial in EGFR exon 20 insertion NSCLC. It will also showcase ARR-002, a dual-target MUC16/NaPi2b tetravalent ADC exhibiting superior in vivo efficacy and favorable tolerability in ovarian cancer models.
1. Firmonertinib Preclinical Characterization
ArriVent's preclinical data reveal high-resolution crystal structures showing firmonertinib's broad EGFR binding and potent inhibition of classical and exon 20 insertion mutations. Xenograft studies in NSCLC models demonstrate strong anti-tumor activity and high brain penetrance, underpinning the ongoing pivotal Phase 3 trial in EGFR exon 20 insertion NSCLC.
2. ARR-002 Dual-Target ADC Efficacy
The novel tetravalent ADC ARR-002 engages both MUC16 and NaPi2b antigens simultaneously, resulting in enhanced internalization and superior in vivo efficacy compared to single-target controls in ovarian cancer xenografts. Tolerability studies in cynomolgus monkeys indicate a wider therapeutic window with reversible hematologic effects at higher doses.
3. AACR Poster Presentation Schedule
ArriVent will present firmonertinib findings on April 21, 2026 (2–5 PM PT, Section 18 Board 9) and ARR-002 data on April 20, 2026 (9 AM–12 PM PT, Section 49 Board 12) during sessions on experimental therapeutics and targeted antigen therapies at the AACR Annual Meeting in San Diego.